RPID — Rapid Micro Biosystems, Inc.

Summary of Rapid Micro Biosystems Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $11.3 million, up 37% year-over-year, marking a quarterly record.
• System Placements: 16 Growth Direct systems placed in Q4, totaling 190 systems globally, with 155 fully validated.
• Product Revenue: Increased 78% to $9.3 million, driven by strong system placements.
• Consumable Revenue: Grew 11% in Q4, with a full-year increase of 17%.
• Recurring Revenue: Increased 15% for the full year, accounting for 53% of total revenue.
• Gross Margin: Q4 gross margin was negatively impacted by inventory-related charges, resulting in a negative 3% margin. Excluding these charges, the margin was positive 7%.
• Net Loss: $12.5 million in Q4, compared to a net loss of $9.7 million in the prior year, primarily due to inventory charges and lower service margins.

2. Strategic Updates and Business Highlights

• Partnerships: Notable expansion of the Growth Direct platform with Samsung Biologics and a record multisystem order from Amgen, highlighting the platform's impact on pharmaceutical manufacturing.
• Collaboration with MilliporeSigma: Progress in establishing customer demo labs and training to enhance sales efforts.
• Innovation: Upcoming launch of a next-generation cloud-native software platform in H2 2026, aimed at enhancing customer experience and providing AI-driven analytics.
• Operational Improvements: Efforts to reduce product costs and improve manufacturing efficiencies are underway, with expected benefits starting in H1 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected between $37 million and $41 million, with anticipated system placements of 30 to 38.
• Gross Margin Expectations: Targeting approximately 20% for the full year, with significant improvements expected in the second half.
• Q1 2026 Revenue: Expected to be at least $7.5 million, with at least 5 system placements.
• Service Revenue: Anticipated to increase in Q3 and Q4, following a slight decrease in Q2.

4. Bad News, Challenges, or Points of Concern

• Inventory Charges: The write-off of unusable consumable inventory negatively impacted Q4 margins and overall profitability.
• Validation Delays: A widening gap between placed and validated systems raises concerns about the speed of customer adoption and validation processes.
• Net Loss: Continued net losses indicate ongoing financial challenges, particularly in managing operational costs and service revenue variability.
• Market Uncertainty: Ongoing uncertainty regarding the timing and scale of customer purchase decisions, especially for larger multisystem orders.

5. Notable Q&A Insights

• Validation Process: Management acknowledged the natural lag between system placement and validation, indicating that improvements in this area are expected as larger orders progress.
• Repeat Customers: Repeat customers like Samsung are anticipated to move through the sales and validation pipeline more quickly than new customers.
• Utilization and Consumables: Expected single-digit year-over-year improvement in consumables pull-through, with potential for larger increases in 2027 as validations ramp up.
• Cost Reductions: Confidence in achieving gross margin targets is bolstered by locked-in cost reductions for key materials, expected to positively impact margins in the latter half of 2026.

Overall, Rapid Micro Biosystems demonstrated strong revenue growth and strategic partnerships while facing challenges related to inventory management and validation timelines. The company remains optimistic about its future growth trajectory and operational improvements.